What is Tahoe?
Tahoe Bio is a biotechnology firm dedicated to the advancement of next-generation allogeneic cell therapies. The company's primary focus is on developing innovative natural killer (NK) cell-based immunotherapies designed for the treatment of various forms of cancer. This strategic capital infusion is expected to accelerate the development and potential commercialization of their novel therapeutic approaches.
How much funding has Tahoe raised?
Tahoe has raised a total of $30M across 1 funding round:
Other Financing Round
$30M
Other Financing Round (2025): $30M with participation from AIX Ventures, General Catalyst, Civilization Ventures, Databricks, Wing Venture Capital, and Amplify Partners
Key Investors in Tahoe
AIX Ventures
AIX Ventures is a venture capital firm focused on investing in seed stage AI startups and partnering with top AI practitioners. The firm aims to support bold founders in transforming industries by turning innovative ideas into enduring companies.
General Catalyst
General Catalyst operates as a venture capital firm focused on identifying and supporting transformational business opportunities across multiple sectors and stages. The firm deploys capital strategically to back entrepreneurs and management teams pursuing ambitious visions that reshape their respective industries.
Civilization Ventures
Civilization Ventures is a venture capital firm that invests in innovative companies within the health tech and biopharma sectors, focusing on preventative, personalized, and regenerative healthcare solutions. Since its inception in 2017, the firm has managed over $200 million in capital and partnered with more than 70 companies.
What's next for Tahoe?
The substantial enterprise-level backing suggests Tahoe Bio is poised for significant scaling and further research and development. This major strategic investment will likely fuel expansion of clinical trials, enhancement of manufacturing capabilities, and the broadening of their therapeutic pipeline. The company's focus on NK cell immunotherapies positions it within a rapidly growing segment of oncology, aiming to provide more effective and targeted cancer treatments.
See full Tahoe company page
